Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Atrial Fibrillation

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and ...

Home May 15, 2018
Home
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018
Feature | Cardiovascular Clinical Studies

May 14, 2018 – New clinical evidance showsΒ common therapy options for psoriasis (PSO), a chronic inflammatory skin ...

Home May 14, 2018
Home
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.
Feature | Cardiac Diagnostics | Steven D. Freedman, M.D., Ph.D.

Β 


In many cases, the diagnosis and management of patients with rare diseases can require the participation of ...

Home May 07, 2018
Home
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Feature | Antiplatelet and Anticoagulation Therapies

May 7, 2018 β€” The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

Home May 07, 2018
Home
Technology | Clinical Decision Support

April 30, 2018 β€” Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their ...

Home April 30, 2018
Home
News | Pharmaceuticals

April 6, 2018 β€” Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its ...

Home April 06, 2018
Home
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18
Feature | ACC | Dave Fornell

There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American College ...

Home March 27, 2018
Home
News | Peripheral Artery Disease (PAD)

March 23, 2018 β€” Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence ...

Home March 23, 2018
Home
News | ACC

March 22, 2018 β€” The experimental drug andexanet was associated with control of serious bleeding in patients taking a ...

Home March 22, 2018
Home
News | ACC

March 20, 2018 β€” Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 β€” During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 β€” Febuxostat, a gout drug that has been in use for nearly a decade, was found to significantly increase ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 β€” The anti-inflammatory drug canakinumab had no effect on rates of newly diagnosed diabetes in people who ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 β€” Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart attack ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 β€” Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broad ...

Home March 20, 2018
Home
Subscribe Now